Product Name:
Chk2-pT68
Product Number:
ab-pk119
Target Full Name: Protein-serine/threonine kinase Chk2 Thr-68 phosphosite
Target Alias: Cds1; CHEK2; CHK2 checkpoint homologue (S. pombe); EC 2.7.11.1; RAD53
Product Type Specific: Chk2 (CHEK2) phosphosite-specific polyclonal antibody
Antibody Code: PK119
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T68
Protein UniProt: O96017
Protein SigNET: Chk2
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Ig Isotype Clone: IgG
Antibody Immunogen Source: Peptide with amino acid sequence surrounding the human Chk2 Thr-68 phosphosite
Antibody Immunogen Sequence: VS(pT)QE
Antibody Immunogen Description: 5 amino acid phosphopeptide corresponding to the human Chk2 T68 phosphosite.
Production Method: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol
Storage Conditions: -20°C
Storage Stability: > 1 year
Product Use: Western blotting, Immunohistochemistry (IHC)
Antibody Dilution Recommended: 2 µg/mL
Antibody Potency: Very strong
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus macaque | Rat | Mouse.
Antibody Positive Control: T68 phosphorylated Chk2
Antibody Specificity: High
Antibody Cross Reactivity: Ocassionally, strong cross-reactivities with ~46 and ~100 kDa proteins can be detected.
Related Product 1: Chk1Selectide kinase substrate peptide (Cat. No.: PE-01BGS90)
Related Product 2: Chk2Selectide kinase substrate peptide (Cat. No.: PE-01BGT95)
Related Product 3: Chk1 S280 phosphorylation antibody (Cat. No.: AB-PK577)
Related Product 4: Chk1 S317 phosphorylation antibody (Cat. No.: AB-PK578)
Related Product 5: Chk1 S345 phosphorylation antibody (Cat. No.: AB-PK579)
Related Product 6: Chk2 T383 phosphorylation antibody (Cat. No.: AB-PK580)
Related Product 7: Chk2 T68 phosphorylation antibody (Cat. No.: AB-PK581)
Scientific Background: Chk2 (CHEK2) is a 65 kDa protein-serine/threonine kinase of the CAMK group and RAD53 family. It is required for cell cycle arrest, activation of DNA repair, and the promotion of apoptosis in response to double-stranded breaks in DNA. It features an N-terminal SQ/TQ cluster domain (SCD), a Forkhead-associated (FHA) domain for protein binding, and a C-terminal kinase domain. The forkhead-associated protein interaction domain essential for activation in response to DNA damage. It is rapidly phosphorylated at Thr-68 by MLTK in response to replication blocks and DNA damage, and activated through autophosphorylation. The response to DNA damage occurs in an ataxia telangiectasia mutated (ATM)-dependent manner. It is phosphorylated at Thr-68 by ATM and ATR. It is also activated by phosphorylation at Ser-19, Thr-26, Ser-28, Ser-33, Ser-35, Thr-383, Thr-387 and Ser-516. The effects of Chk2 are mediated through the phosphorylation and inhibition of various downstream effectors, including CDC25A, CDC25B, and CDC25C. Chk2 phosphorylates CDC25C at Ser-216 and inhibits this phosphatase (blocking entry into mitosis), p53 at Thr-18 and Ser-20 (inducing cell cycle arrest in G1), and BRCA1 (maintaining survival after DNA damage). Twelve splice variant isoforms have been described for human Chk2. High expression is observed in testis, spleen, tonsils, colon and peripheral blood leukocytes, and is notably absent in brain and spinal cord. Orthologues of Chk2 are amongst the most highly conserved protein kinases in animals, plants, fungi and unicellular eukaryotes. Expression of wild-type Chk2 leads to increased p53 stabilization after DNA damage, whereas expression of a dominant-negative Chk2 mutant abrogated both phosphorylation of p53 on S20 and p53 stabilization. Loss of function mutants of ChK2 can cause Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype often found with p53 mutations as well. Familial mutations also associated with prostate and breast cancers, and mutations also occur in a variety of sporadic cancers and cell lines. This description may include information annotated by UniProt and/or Google AI.